Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit
Oncology Shines And Antivirals Recover In Q3
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.